Oruka Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Oruka Therapeutics, Inc. (ORKA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$9.69 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-19.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2015-03-19
- Oruka Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2014-12-31 was -$2.61M.
- Oruka Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2014-09-30 was -$2.28M.
- Oruka Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2014-06-30 was -$2.40M.
- Oruka Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2014-03-31 was -$2.39M.
- Oruka Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2014 was -$9.69M.
- Oruka Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2013 was -$8.96M.
- Oruka Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2012 was -$4.32M.
- Oruka Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2011 was -$5.36M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 114 month | Net Income (Loss) Available to Common Stockholders, Basic 117 month | Net Income (Loss) Available to Common Stockholders, Basic 120 month | Net Income (Loss) Available to Common Stockholders, Basic 123 month | Net Income (Loss) Available to Common Stockholders, Basic 126 month | Net Income (Loss) Available to Common Stockholders, Basic 129 month | Net Income (Loss) Available to Common Stockholders, Basic 132 month | Net Income (Loss) Available to Common Stockholders, Basic 135 month | Net Income (Loss) Available to Common Stockholders, Basic 138 month | Net Income (Loss) Available to Common Stockholders, Basic 141 month | Net Income (Loss) Available to Common Stockholders, Basic 144 month | Net Income (Loss) Available to Common Stockholders, Basic 147 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-12-31 | -$2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-19 | -$4.89M derived: sum of 2 quarters · filed 2015-03-19 | -$7.30M derived: sum of 3 quarters · filed 2015-03-19 | -$9.69M 10-K · filed 2015-03-19 | ||||||||||||
| 2014-09-30 | -$2.28M 10-Q · filed 2014-11-12 | -$4.69M derived: sum of 2 quarters · filed 2014-11-12 | -$7.08M 10-Q · filed 2014-11-12 | -$10.02M derived: sum of 4 quarters · filed 2015-03-19 | ||||||||||||
| 2014-06-30 | -$2.40M 10-Q · filed 2014-08-13 | -$4.79M 10-Q · filed 2014-08-13 | -$7.74M derived: sum of 3 quarters · filed 2015-03-19 | -$9.46M derived: sum of 4 quarters · filed 2015-03-19 | ||||||||||||
| 2014-03-31 | -$2.39M 10-Q · filed 2014-05-13 | -$5.33M derived: sum of 2 quarters · filed 2015-03-19 | -$7.06M derived: sum of 3 quarters · filed 2015-03-19 | -$10.28M derived: sum of 4 quarters · filed 2015-03-19 | -$80.37M 10-Q · filed 2014-05-13 | |||||||||||
| 2013-12-31 | -$2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-19 | -$4.67M derived: sum of 2 quarters · filed 2015-03-19 | -$7.89M derived: sum of 3 quarters · filed 2015-03-19 | -$8.96M 10-K · filed 2015-03-19 | -$77.98M 10-K · filed 2014-03-20 | |||||||||||
| 2013-09-30 | -$1.72M 10-Q · filed 2014-11-12 | -$4.95M derived: sum of 2 quarters · filed 2014-11-12 | -$6.02M 10-Q · filed 2014-11-12 | -$6.86M derived: sum of 4 quarters · filed 2014-11-12 | -$75.04M 10-Q · filed 2013-11-13 | |||||||||||
| 2013-06-30 | -$3.23M 10-Q · filed 2014-08-13 | -$4.30M 10-Q · filed 2014-08-13 | -$5.14M derived: sum of 3 quarters · filed 2014-08-13 | -$6.06M derived: sum of 4 quarters · filed 2014-08-13 | -$73.32M 10-Q · filed 2013-08-13 | |||||||||||
| 2013-03-31 | -$1.07M 10-Q · filed 2014-05-13 | -$1.91M derived: sum of 2 quarters · filed 2014-05-13 | -$2.84M derived: sum of 3 quarters · filed 2014-05-13 | -$3.98M derived: sum of 4 quarters · filed 2014-05-13 | -$70.09M 10-Q · filed 2013-05-13 | |||||||||||
| 2012-12-31 | -$840.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20 | -$1.77M derived: sum of 2 quarters · filed 2014-03-20 | -$2.91M derived: sum of 3 quarters · filed 2014-03-20 | -$4.32M 10-K · filed 2014-03-20 | -$69.02M 10-K · filed 2013-03-21 | |||||||||||
| 2012-09-30 | -$927.00K 10-Q · filed 2013-11-13 | -$2.07M derived: sum of 2 quarters · filed 2013-11-13 | -$3.48M 10-Q · filed 2013-11-13 | -$5.11M derived: sum of 4 quarters · filed 2013-11-13 | -$68.18M 10-Q · filed 2012-11-13 | |||||||||||
| 2012-06-30 | -$1.15M 10-Q · filed 2013-08-13 | -$2.55M 10-Q · filed 2013-08-13 | -$4.18M derived: sum of 3 quarters · filed 2013-08-13 | -$6.00M derived: sum of 4 quarters · filed 2013-08-13 | -$67.25M 10-Q · filed 2012-08-13 | |||||||||||
| 2012-03-31 | -$1.41M 10-Q · filed 2013-05-13 | -$3.04M derived: sum of 2 quarters · filed 2013-05-13 | -$4.86M derived: sum of 3 quarters · filed 2013-05-13 | -$4.57M derived: sum of 4 quarters · filed 2013-05-13 | -$66.11M 10-Q · filed 2012-05-14 | |||||||||||
| 2011-12-31 | -$1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-21 | -$3.45M derived: sum of 2 quarters · filed 2013-03-21 | -$3.16M derived: sum of 3 quarters · filed 2013-03-21 | -$5.36M 10-K · filed 2013-03-21 | -$64.70M 10-K · filed 2012-03-27 | |||||||||||
| 2011-09-30 | -$1.82M 10-Q · filed 2012-11-13 | -$1.53M derived: sum of 2 quarters · filed 2012-11-13 | -$3.73M 10-Q · filed 2012-11-13 | -$5.33M derived: sum of 4 quarters · filed 2012-11-13 | -$63.07M 10-Q · filed 2011-11-14 | |||||||||||
| 2011-06-30 | $294.00K 10-Q · filed 2012-08-13 | -$1.91M 10-Q · filed 2012-08-13 | -$3.51M derived: sum of 3 quarters · filed 2012-08-13 | -$5.61M derived: sum of 4 quarters · filed 2012-08-13 | -$61.25M 10-Q · filed 2011-08-15 | |||||||||||
| 2011-03-31 | -$2.21M 10-Q · filed 2012-05-14 | -$3.80M derived: sum of 2 quarters · filed 2012-05-14 | -$5.91M derived: sum of 3 quarters · filed 2012-05-14 | -$8.18M derived: sum of 4 quarters · filed 2012-05-14 | ||||||||||||
| 2010-12-31 | -$1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-27 | -$3.70M derived: sum of 2 quarters · filed 2012-03-27 | -$5.97M derived: sum of 3 quarters · filed 2012-03-27 | -$8.42M 10-K · filed 2012-03-27 | ||||||||||||
| 2010-09-30 | -$2.11M 10-Q · filed 2011-11-14 | -$4.38M derived: sum of 2 quarters · filed 2011-11-14 | -$6.83M 10-Q · filed 2011-11-14 | |||||||||||||
| 2010-06-30 | -$2.27M 10-Q · filed 2011-08-15 | -$4.72M 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |